Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey
- PMID: 22790905
- DOI: 10.1007/s10620-012-2289-y
Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey
Abstract
Background: Crohn's disease (CD) and ulcerative colitis (UC) are chronic, debilitating conditions that can have important economic and clinical implications.
Aim: To quantify individual and national estimates of the health care and patient out-of-pocket (OOP) costs of CD and UC.
Methods: In a retrospective study using 1996 to 2009 data from the Medical Expenditure Panel Survey, individuals' self-reported health conditions were mapped to International Classification of Diseases, Ninth Revision, Clinical Modification diagnostic codes. Individuals with a code of 555.x (CD) or 556.x (UC) were identified. Health care services and costs included prescriptions and inpatient, outpatient, emergency room, office, and home health services. OOP costs were the portion of individuals' total payments for health care services.
Results: There were 358 individuals with CD (mean age 49.0 years; 55 % female), 198 individuals with UC (mean age 47.1 years; 64 % female), and 206,993 individuals without inflammatory bowel disease (IBD) (mean age 48.2 years; 58 % female). Annual per capita health insurer and OOP costs for individuals with CD were greater than those without IBD ($9,526 versus $3,781, p < 0.001 and $1,603 versus $866, p < 0.001, respectively). Health insurer and OOP costs were greater for UC compared with those without IBD ($6,443 versus $3,781, p < 0.001 and $1,263 versus $866, p < 0.001, respectively). US national aggregate annual estimates of health insurer, OOP, and total direct costs secondary to CD are $2.04 billion, $0.26 billion, and $2.29 billion, respectively. Aggregate health insurer, OOP, and total direct costs attributable to UC are $0.53 billion, $0.07 billion, and $0.61 billion, respectively.
Conclusions: The direct costs associated with CD and UC are substantial. The extent to which appropriate diagnosis and treatment reduces the total health care costs for individuals with CD or UC should be examined.
Comment in
-
The economic burden of inflammatory bowel disease: clear problem, unclear solution.Dig Dis Sci. 2012 Dec;57(12):3042-4. doi: 10.1007/s10620-012-2417-8. Dig Dis Sci. 2012. PMID: 23086111 No abstract available.
Similar articles
-
Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.Gastroenterology. 2008 Dec;135(6):1907-13. doi: 10.1053/j.gastro.2008.09.012. Epub 2008 Sep 17. Gastroenterology. 2008. PMID: 18854185 Free PMC article.
-
The direct healthcare insurer and out-of-pocket expenditures of psoriasis: evidence from a United States national survey.J Dermatolog Treat. 2012 Aug;23(4):240-54. doi: 10.3109/09546634.2010.550911. Epub 2011 Jul 31. J Dermatolog Treat. 2012. PMID: 21801089
-
Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn's Disease in Italy.Adv Ther. 2024 Jun;41(6):2282-2298. doi: 10.1007/s12325-024-02840-x. Epub 2024 Apr 15. Adv Ther. 2024. PMID: 38619721 Free PMC article.
-
How expensive is inflammatory bowel disease? A critical analysis.World J Gastroenterol. 2008 Nov 21;14(43):6641-7. doi: 10.3748/wjg.14.6641. World J Gastroenterol. 2008. PMID: 19034966 Free PMC article. Review.
-
The economic and quality-of-life burden of Crohn's disease in Europe and the United States, 2000 to 2013: a systematic review.Dig Dis Sci. 2015 Feb;60(2):299-312. doi: 10.1007/s10620-014-3368-z. Epub 2014 Sep 26. Dig Dis Sci. 2015. PMID: 25258034 Review.
Cited by
-
Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers.Front Pharmacol. 2022 Jan 3;12:775084. doi: 10.3389/fphar.2021.775084. eCollection 2021. Front Pharmacol. 2022. PMID: 35046810 Free PMC article. Review.
-
Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents.Aliment Pharmacol Ther. 2021 Aug;54(3):234-248. doi: 10.1111/apt.16445. Epub 2021 Jun 11. Aliment Pharmacol Ther. 2021. PMID: 34114667 Free PMC article. Review.
-
Spray-Dried Formulation of Epicertin, a Recombinant Cholera Toxin B Subunit Variant That Induces Mucosal Healing.Pharmaceutics. 2021 Apr 18;13(4):576. doi: 10.3390/pharmaceutics13040576. Pharmaceutics. 2021. PMID: 33919585 Free PMC article.
-
Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study.BMC Rheumatol. 2020 Apr 2;4:16. doi: 10.1186/s41927-020-0115-2. eCollection 2020. BMC Rheumatol. 2020. PMID: 32266326 Free PMC article.
-
Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil.World J Gastroenterol. 2019 Oct 14;25(38):5862-5882. doi: 10.3748/wjg.v25.i38.5862. World J Gastroenterol. 2019. PMID: 31636478 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
